Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
CC transcript

Oncternal Therapeutics, Inc. (GTXI) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/12/2018 BW GTx Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
11/14/2017 BW GTx Provides Corporate Update and Reports Third Quarter 2017 Financial Results
09/25/2017 BW GTx Announces Webcast of Corporate Presentation at the 2017 Cantor Fitzgerald Global Healthcare Conference
08/14/2017 BW GTx Provides Corporate Update and Reports Second Quarter 2017 Financial Results
05/15/2017 BW GTx Provides Corporate Update and Reports First Quarter 2017 Financial Results
03/15/2017 BW GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2016 Financial Results
03/07/2017 BW GTx, Inc. to Report Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017
08/11/2011 BW GTx Announces Webcast of Corporate Presentation at the 2011 Wedbush Life Sciences Conference
06/30/2011 BW GTx Announces Upcoming Presentations of Effects of Ostarine™ in Non-Small Cell Lung Cancer Patients at World Conference on Lung Cancer
06/20/2011 BW GTx Initiates Phase IIb Clinical Trial Evaluating Oral Capesaris™ Tablets Versus Lupron Depot® for First Line Treatment of Advanced Prostate Cancer
06/06/2011 BW GTx Announces Agreement with FDA on Phase III Clinical Development Plan Evaluating Ostarine™ (GTx-024) for the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer
06/01/2011 BW GTx Announces Webcast of Corporate Presentation at the Jefferies 2011 Global Healthcare Conference
05/18/2011 BW GTx Announces ASCO Presentations Highlighting Effects of Ostarine™ on Physical Function and Survival in Patients with Non-Small Cell Lung Cancer
05/17/2011 BW GTx Presents Preclinical Study Results Demonstrating That Capesaris™ (GTx-758) Chronic Treatment Does Not Cause Gynecomastia in Male Primates
05/09/2011 BW GTx Provides Corporate Update and Reports First Quarter 2011 Financial Results
05/02/2011 BW GTx, Inc. To Host First Quarter 2011 Financial Results Conference Call and Webcast
12/13/2010 BW GTx Presents Results of the Capesaris™ (GTx-758) Phase II Proof of Concept Pharmacokinetic-Pharmacodynamic Clinical Trial
11/15/2010 BW GTx Presents Preclinical Studies of GTx-758, a Selective Estrogen Receptor Alpha Agonist for First Line Treatment of Advanced Prostate Cancer, and GTx-230, an Orally Available Tubulin Antagonist for Cancer Refractory to Taxane and Vinca Alkaloid Therapy
11/11/2010 BW GTx Announces Corporate Presentation at the Lazard Capital Markets Annual Healthcare Conference
11/09/2010 BW GTx, Inc. Reports Third Quarter 2010 Corporate Results
11/08/2010 BW GTx Appoints Dr. Barry Furr to the Board of Directors
11/03/2010 BW GTx Awarded $1.2 Million in Grants for Qualifying Therapeutic Discovery Projects
10/27/2010 BW GTx Announces Pricing of Public Offering of Common Stock
10/26/2010 BW GTx Announces Proposed Public Offering of Common Stock
09/16/2010 BW GTx Announces Corporate Presentation at the UBS Global Life Sciences Conference
09/15/2010 BW GTx Announces That GTx-758, a Novel Oral Selective Estrogen Receptor Alpha Agonist Being Developed to Treat Advanced Prostate Cancer, Induced Medical Castration in a Phase II PK/PD Clinical Trial
08/09/2010 BW GTx, Inc. Reports Second Quarter 2010 Corporate Results
07/26/2010 BW GTx, Inc. Announces Second Quarter 2010 Financial Results Conference Call and Webcast
06/21/2010 BW GTx Announces Ostarine Increased Lean Body Mass and Leg Press Strength in Head to Head Clinical Study
04/28/2010 BW GTx, Inc. Announces First Quarter 2010 Financial Results Conference Call and Webcast
03/23/2010 BW GTx and Ipsen Expand Partnership
03/15/2010 BW GTx Provides Corporate Update and Reports 2009 Financial Results
03/02/2010 BW GTx, Inc. Announces Fourth Quarter and Year End 2009 Financial Results Conference Call and Webcast

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy